JIA-KANG WANGCHUNG-MAY YANGCHANG-PING LINShan Y.-D.Lo A.Y.HWEI-FANG TIEN2021-01-042021-01-0420060021-5155https://www.scopus.com/inward/record.uri?eid=2-s2.0-33749319975&doi=10.1007%2fs10384-005-0327-4&partnerID=40&md5=0e071edd1a3c884b53349475d9b9ac2dhttps://scholars.lib.ntu.edu.tw/handle/123456789/537507Background: To demonstrate the efficacy of intravitreal methotrexate for treating intraocular lymphoma. Case: A 55-year-old immunocompetent Asian man was diagnosed with intraocular lymphoma. Observations: The patient was initially managed by intravenous administration of high-dose methotrexate. Because vitreous cells persisted after systemic chemotherapy, methotrexate was given intravitreally thereafter. There was only self-limited corneal epitheliopathy without major complications following intraocular injections. Ocular remission was sustained during a 21-month follow-up. Conclusion: Intravitreal methotrexate is an effective, repeatable, and safe treatment for intraocular lymphoma. ? Japanese Ophthalmological Society 2006.Chemotherapy; Intraocular lymphoma; Intravitreal injection; Methotrexate; Primary central nervous system lymphoma[SDGs]SDG3methotrexate; adult; article; cancer chemotherapy; cancer regression; case report; cornea disease; cornea epitheliopathy; cornea epithelium; drug efficacy; drug megadose; drug safety; eye pain; follow up; human; immunocompetence; iritis; lymphoma; male; priority journal; vitreous body; vitreous disease; vitritis; Antimetabolites, Antineoplastic; Biopsy; Diagnosis, Differential; Eye Neoplasms; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Humans; Injections; Lymphoma, B-Cell; Male; Methotrexate; Middle Aged; Taiwan; Vitreous Bodyjournal article10.1007/s10384-005-0327-4170137032-s2.0-33749319975